Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval for Diabetes Mellitus

Shots:

• The US FDA has granted approval to Myxredlin as the first ready-to-use insulin for IV infusion in the hospital with an extended shelf-life of 30 days @25◦C or 24 mos. if refrigerated @2-8◦C
• Myxredlin utilizes Baxter’s Galaxy container technology which is a non-PVC and non-DEHP system enabling premixed medicines to have a longer shelf life at room temperature
• Myxredlin (insulin human in 0.9% sodium chloride injection) is available in a standardized concentration of 100 units/100 mL in a flexible plastic container indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus

Click here to read full press release/ article | Ref: Baxter | Image: Baxter